Analyzing MiNK Therapeutics (NASDAQ:INKT) and Evaxion Biotech A/S (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Risk & Volatility

Evaxion Biotech A/S has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500.

Earnings & Valuation

This table compares Evaxion Biotech A/S and MiNK Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	$3.30 million	1.60	-$22.12 million	($0.29)	-3.10
MiNK Therapeutics	N/A	N/A	-$22.46 million	($0.39)	-1.87

Evaxion Biotech A/S has higher revenue and earnings than MiNK Therapeutics. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.0% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Comparatively, 20.6% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Evaxion Biotech A/S and MiNK Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
MiNK Therapeutics	0	0	2	0	3.00

Evaxion Biotech A/S presently has a consensus target price of $55.00, suggesting a potential upside of 6,011.11%. MiNK Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 789.19%. Given Evaxion Biotech A/S’s higher possible upside, research analysts clearly believe Evaxion Biotech A/S is more favorable than MiNK Therapeutics.

Profitability

This table compares Evaxion Biotech A/S and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	-347.83%	N/A	-79.40%
MiNK Therapeutics	N/A	N/A	-189.14%

Summary

Evaxion Biotech A/S beats MiNK Therapeutics on 7 of the 10 factors compared between the two stocks.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.